Lantern Pharma: FDA Grants Additional Orphan Drug Designation For LP-184 - Quick Facts

(RTTNews) - Clinical-stage biopharmaceutical company Lantern Pharma (LTRN) said the FDA has granted LP-184 Orphan Drug Designation for the treatment of glioblastoma multiforme and other malignant gliomas. Previously, LP-184 was granted Orphan Drug Designation for the treatment of pancreatic cancer.

LP-184 is a small molecule drug candidate and next generation alkylating agent that preferentially damages DNA in cancer cells that over-express certain biomarkers or that harbor mutations in DNA repair pathways.

Shares of Lantern Pharma were up 5% in pre-market trade on Monday.